Share price of the Inovio Pharmaceuticals (NYSEMKT:INO), a new bio-pharmaceutical company, soared on 1/28/2016 with 7.6% and again 15.6% on 1/29/2016 (the last day of the week and the last of the month) to $6.68 on an above-average trading volume, as well as even more surge (10%) during the after-hour trading on the same day.
These a total of >25% gain was due to the fact that the company, the Inovio Pharmaceuticals , in collaboration with Canadian and American scientists, will succeed in developing a new vaccine against the Zika virus, a horrible human disease virus. The consortium working on the vaccine includes University of Pennsylvania, led by scientist David Weiner, University of Laval, led by Gary Kobinger, Inovio Pharmaceuticals Inc and South Korea's GeneOne Life Science. For the readers, if you do not know these names, please do trust that the University of Pennsylvania is considered as a top-ranked and highly ranked academic institute.
We anticipate that the share price will continue to be in an up-going trend, with some minor fluctuation, through the summer of 2016, due to the facts: 1. this company has also several other promising vaccine; 2. its clinical trial on Zika is to be started; and 3. the development of this vaccine will be successful with certainty, to protect potentially more than 4,000,000 Americans at risk, as well as many world-wide.
Encourage readers to read this paragraph I cited from company's website: Dr. J. Joseph Kim, Inovio President and CEO, said: "Our broad experience with DNA-based immunotherapies and with MERS specifically suggests we can potentially make an important contribution to developing such a solution. As demonstrated by our recent vaccine development efforts for Ebola, we can readily apply Inovio's technology to target other threatening infectious threats like MERS and Zika virus as well as other emergent infectious diseases."
The company is to complete its testing of a Zika vaccine in mice and monkeys by the third quarter of this year before moving to a Phase 1 study in Q4,as reported on the news (www.benzinga.com/general/biotech/16/01/6...-).
The vaccine can be used in an emergency, if needed, as early as in October of 2016. It was reported that the company plans to produce between 5,000 and 10,000 doses by Q3 of this year., but haven't determined when a product could be used in an emergency.
The U.S. and international governments take efforts and push for the development of this vaccine, and thus there are several companies show interests for this program,including INO, GlaxoSmithKline(NYSE:GSK) and Sanofi(NYSE:SNY). Of these three pharmaceutical companies, the company that appears to be the farthest along is a $500 million market cap biotech named Inovio Pharmaceuticals , which has been outperforming this week. Stocks has been soaring as Wall street has shown interest in this novel vaccine and its life-saving potential as well as the huge potential profits.
As a medical professional, the writer of this article fully understand that the vaccination is powerful life-saver, and Zika virus being a harm to human beings. As reported by CDC, Zika virus is spread to people through mosquito bites. In May 2015, the Pan American Health Organization (PAHO) issued an alert regarding the first confirmed Zika virus infection in Brazil. The outbreak in Brazil led to reports of Guillain-Barré syndrome (devastating) and pregnant women giving birth to babies with birth defects and poor pregnancy outcomes (major medical outcomes). (www.cdc.gov/zika/)
There is no curable treatment for this condition and there is no proven vaccine available either. An estimated 80 percent of people infected have no symptoms, making it difficult for pregnant women to know whether they have been infected. The Zika virus has been linked to many types of severe birth defects in thousands of infants. Therefore, the use of vaccine is of a great value.
For general readers, the development of a vaccine, unlike a drug development, is using the straight-forward strategies, which of no failure. Therefore, soon or later, the vaccine will be out on the market and profits will be in hands.
The World Health Organization (WHO) said recently that Zika is spreading "explosively" and could affect as many as four million people in the Americas. We need the vaccine, human beings need the vaccine, and market will recognize the vaccine and its usefulness and huge profits.
Inovio, as a company with entensive experience in vaccine development, has an advanced technology and technical platform that can easily and readily generate the Zika vaccines. These vaccines are to be practically useful, and any of reproductive women actually will benefit from being vaccinated with it.
These viruses are persistent threats to the world, and I'm glad Inovio is developing preventive measures. In addition to the fact that this Inovio company has this Zika virus coming, the company also develop other vaccines at the same time, such as MERS vaccine, which could also hold promise for future (fortune.com/2016/01/28/zika-virus-vaccine/). They have developed Ebola vaccine as well. This company has had several clinical trials on going.
FYI: Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
Interestingly and more importantly, I would like our readers to check out the following article, which just came out on 1/31/2016, and emphasizes that the Inovio is also working on a novel and universal Flu vaccine. (www.nasdaq.com/article/3-feverishly-bad-...). If this succeeds, you would not have to do flu shots every year, which is the "one shot, cover all" type strategy, and will be worthy of big dollars.
(Inovio Pharmaceuticals is utilizing its SynCon DNA-based platform to develop a universal vaccine that would, in theory, cover the most common seasonal influenza flu subtypes, as well as pandemic potential subtypes, such as H5N1. Because Inovio's platform involves DNA-based vaccines, it should be able to mix and match subtypes with ease on an as-needed basis. Multiple clinical studies are ongoing.) Read more: http://www.fool.com/investing/general/2016/01/31/3-feverishly-bad-flu-myths-that-should-be-put-to-r.aspx#ixzz3ys3QokE2 )
I am holding INO stock since 1/29/2016.
Disclosure: I am/we are long INO.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.